The protective side of progesterone

by Ferretti, Gianluigi, Felici, Alessandra, Cognetti, Francesco
Published 2007

First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?

by Fabi, Alessandra, Malaguti, Paola, Vari, Sabrina, Cognetti, Francesco
Published in J Exp Clin Cancer Res (2016)

The withdrawal from oncogenetic counselling and testing for hereditary and familial breast and ovarian cancer. A descriptive study of an Italian sample

by Cognetti Francesco, Sega Fabio, Maggi Gabriella, Vigna Cristina, Caruso Anita, Savarese Antonella
Published 2008-11-01

Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?

by Catania, Giovanna, Malaguti, Paola, Gasparro, Simona, Cognetti, Francesco, Vidiri, Antonello, Fabi, Alessandra
Published in Oncology (2018)

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives

by Infante, Marco, Fabi, Alessandra, Cognetti, Francesco, Gorini, Stefania, Caprio, Massimiliano, Fabbri, Andrea
Published in J Exp Clin Cancer Res (2019)

The withdrawal from oncogenetic counselling and testing for hereditary and familial breast and ovarian cancer. A descriptive study of an Italian sample

by Caruso, Anita, Vigna, Cristina, Maggi, Gabriella, Sega, Fabio Massimo, Cognetti, Francesco, Savarese, Antonella
Published 2008

KRAS Early Testing: Consensus Initiative and Cost-Effectiveness Evaluation for Metastatic Colorectal Patients in an Italian Setting

by Barone, Carlo, Pinto, Carmine, Normanno, Nicola, Capussotti, Lorenzo, Cognetti, Francesco, Falcone, Alfredo, Mantovani, Lorenzo
Published 2014

Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis

by RUSSILLO, MICHELANGELO, FERRETTI, GIANLUIGI, VIDIRI, ANTONELLO, GASPARRO, SIMONA, COGNETTI, FRANCESCO, PELLEGRINI, DOMENICA, FABI, ALESSANDRA
Published in In Vivo (2018)

Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?

by Stagno, Anna, Vari, Sabrina, Annovazzi, Alessio, Anelli, Vincenzo, Russillo, Michelangelo, Cognetti, Francesco, Ferraresi, Virginia
Published in Front Oncol (2021)

Targeting targeted agents: open issues for clinical trial design

by Giannarelli Diana, Cuppone Federica, Carlini Paolo, Di Maio Massimo, Bria Emilio, Cognetti Francesco, Milella Michele
Published 2009-05-01

Targeting targeted agents: open issues for clinical trial design

by Bria, Emilio, Di Maio, Massimo, Carlini, Paolo, Cuppone, Federica, Giannarelli, Diana, Cognetti, Francesco, Milella, Michele
Published 2009

Subjective versus objective risk in genetic counseling for hereditary breast and/or ovarian cancers

by Caruso, Anita, Vigna, Cristina, Marozzo, Bruna, Sega, Fabio M, Sperduti, Isabella, Cognetti, Francesco, Savarese, Antonella
Published 2009

Fixed-Dose-Rate Gemcitabine: A Viable First-Line Treatment Option for Advanced Pancreatic and Biliary Tract Cancer

by Milella, Michele, Gelibter, Alain J., Pino, Maria Simona, Bossone, Giandominik, Marolla, Paolo, Sperduti, Isabella, Cognetti, Francesco
Published 2010

Oligometastatic Breast Cancer: How to Manage It?

by Barberi, Vittoria, Pietragalla, Antonella, Franceschini, Gianluca, Marazzi, Fabio, Paris, Ida, Cognetti, Francesco, Masetti, Riccardo, Scambia, Giovanni, Fabi, Alessandra
Published in J Pers Med (2021)

Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients

by Ferraresi, Virginia, Nuzzo, Carmen, Zoccali, Carmine, Marandino, Ferdinando, Vidiri, Antonello, Salducca, Nicola, Zeuli, Massimo, Giannarelli, Diana, Cognetti, Francesco, Biagini, Roberto
Published 2010

A Rare Case of Pituitary Melanoma Metastasis: A Dramatic and Prolonged Response to Dabrafenib-Trametinib Therapy

by Mormando, Marilda, Puliani, Giulia, Barnabei, Agnese, Lauretta, Rosa, Bianchini, Marta, Chiefari, Alfonsina, Russillo, Michelangelo, Cognetti, Francesco, Romano, Luisa, Appetecchia, Marialuisa
Published in Front Endocrinol (Lausanne) (2020)

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study

by Lazzaro, Carlo, Bordonaro, Roberto, Cognetti, Francesco, Fabi, Alessandra, De Placido, Sabino, Arpino, Grazia, Marchetti, Paolo, Botticelli, Andrea, Pronzato, Paolo, Martelli, Elisa
Published 2013

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer

by Vaccaro, Vanja, Bria, Emilio, Sperduti, Isabella, Gelibter, Alain, Moscetti, Luca, Mansueto, Giovanni, Ruggeri, Enzo Maria, Gamucci, Teresa, Cognetti, Francesco, Milella, Michele
Published 2013

Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies

by Tortora, Giampaolo, Bianco, Roberto, Daniele, Gennaro, Ciardiello, Fortunato, McCubrey, James A, Ricciardi, Maria Rosaria, Ciuffreda, Ludovica, Cognetti, Francesco, Tafuri, Agostino, Milella, Michele
Published 2007

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination wit...

by Fabi Alessandra, Russillo Michelangelo, Ferretti Gianluigi, Metro Giulio, Nisticò Cecilia, Papaldo Paola, De Vita Ferdinando, D’Auria Giuliana, Vidiri Antonello, Giannarelli Diana, Cognetti Francesco
Published 2012-10-01